Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are at least 18 years old (or the legal age of consent in the country where the trial is taking place)
• People whose overall health and ability to carry out daily activities meets a specific level, as measured by a standard oncology scoring system (the required level varies depending on which part of the trial a person is being considered for)
• People who have been formally diagnosed with Multiple Myeloma according to established international diagnostic guidelines
• People whose Multiple Myeloma can be measured through specific blood or urine tests at the start of the trial
• People whose organs (including liver and kidneys) and bone marrow are functioning at an adequate level, as assessed through blood tests at the start of the trial
• People who have already received a certain number of prior treatments for Multiple Myeloma (at least 3 prior treatment lines for one part of the trial, or between 1 and 3 prior treatment lines for other parts), with additional specific requirements depending on which part of the trial applies

Who may not be able to join:

• People who have certain related blood or protein disorders, including amyloidosis, plasma cell leukaemia, Waldenström Macroglobulinaemia, POEMS syndrome, or smouldering Multiple Myeloma
• People who are showing signs that Multiple Myeloma has spread to the central nervous system (brain or spinal cord)
• People with a known diagnosis of COPD (chronic obstructive pulmonary disease), or a history of a lung condition called interstitial lung disease or pneumonitis
• People with moderate or severe persistent asthma in the past 5 years, or asthma of any type that is not well controlled
• People with serious heart or cardiovascular disease that is not adequately managed
• People with a history of an immune deficiency disease
• People with nerve damage in the hands or feet (peripheral neuropathy) that is at or above a certain severity level
• People whose Multiple Myeloma did not respond to any treatment from the very beginning (known as primary refractory Multiple Myeloma)
• People who have previously received a specific type of treatment targeting GPRC5D, or any treatment containing a substance called MMAE
• People who have previously had an allogeneic (donor) stem cell transplant, or who have had an autologous (own cells) stem cell transplant within the 3 months before starting the trial
• People who have had another type of cancer (other than Multiple Myeloma) within the 3 years before starting the trial (some exceptions may apply — confirm with trial site)
• People with a history of a serious brain infection caused by the JC virus (known as PML)
• People who have a known allergy or severe sensitivity to the study drug (AZD0305), its ingredients, or other medications used in the trial, or who have had a severe allergic reaction to a monoclonal antibody treatment in the past
• People who have an uncontrolled serious illness, including active infections currently requiring treatment with antibiotics or other medications

Important: Always verify eligibility with the trial site directly before applying.